MA55081A - <smallcaps/>? ? ?pneumocystis? ? ? ? ?antifongiques triterpénoïdes pour le traitement ou la prévention de la pneumonie àspp - Google Patents

<smallcaps/>? ? ?pneumocystis? ? ? ? ?antifongiques triterpénoïdes pour le traitement ou la prévention de la pneumonie àspp

Info

Publication number
MA55081A
MA55081A MA055081A MA55081A MA55081A MA 55081 A MA55081 A MA 55081A MA 055081 A MA055081 A MA 055081A MA 55081 A MA55081 A MA 55081A MA 55081 A MA55081 A MA 55081A
Authority
MA
Morocco
Prior art keywords
smallcaps
triterpenoid
pneumocystis
antifungals
pneumonia
Prior art date
Application number
MA055081A
Other languages
English (en)
French (fr)
Inventor
Gonzalez David A Angulo
Stephen Andrew Barat
Original Assignee
Scynexis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scynexis Inc filed Critical Scynexis Inc
Publication of MA55081A publication Critical patent/MA55081A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
MA055081A 2019-02-27 2020-02-25 <smallcaps/>? ? ?pneumocystis? ? ? ? ?antifongiques triterpénoïdes pour le traitement ou la prévention de la pneumonie àspp MA55081A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962811456P 2019-02-27 2019-02-27

Publications (1)

Publication Number Publication Date
MA55081A true MA55081A (fr) 2022-01-05

Family

ID=70005768

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055081A MA55081A (fr) 2019-02-27 2020-02-25 <smallcaps/>? ? ?pneumocystis? ? ? ? ?antifongiques triterpénoïdes pour le traitement ou la prévention de la pneumonie àspp

Country Status (15)

Country Link
US (1) US12594266B2 (cg-RX-API-DMAC7.html)
EP (1) EP3930716B1 (cg-RX-API-DMAC7.html)
JP (1) JP7581219B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210133241A (cg-RX-API-DMAC7.html)
CN (1) CN113631165A (cg-RX-API-DMAC7.html)
AU (1) AU2020228036B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021016876A2 (cg-RX-API-DMAC7.html)
CA (1) CA3131298A1 (cg-RX-API-DMAC7.html)
EA (1) EA202192344A1 (cg-RX-API-DMAC7.html)
ES (1) ES3055272T3 (cg-RX-API-DMAC7.html)
IL (1) IL285839A (cg-RX-API-DMAC7.html)
MA (1) MA55081A (cg-RX-API-DMAC7.html)
MX (2) MX2021010311A (cg-RX-API-DMAC7.html)
TW (1) TWI910099B (cg-RX-API-DMAC7.html)
WO (1) WO2020176527A1 (cg-RX-API-DMAC7.html)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK173802B1 (da) * 1988-09-12 2001-11-05 Merck & Co Inc Præparat til behandling af Pneumocystis carinii infeksioner og anvendelse af et cyclohexapeptid til fremstilling af et lægemiddel mod Pneumocystis carinii infektioner
US5166135A (en) 1988-09-12 1992-11-24 Merck & Company, Inc. Method for the control of pneumocystis carinii
US5756472A (en) 1996-01-31 1998-05-26 Merck & Co., Inc. Antifungal agent obtained from hormonema
ES2402659T3 (es) 2006-04-03 2013-05-07 Merck Sharp & Dohme Corp. Derivados de enfumafungina como agentes antifúngicos
WO2010019204A1 (en) 2008-08-12 2010-02-18 Merck Sharp & Dohme Corp. Antifungal agents
CN108883152A (zh) * 2016-01-08 2018-11-23 奇达拉治疗公司 防止和治疗肺孢子虫感染的方法
JP7263313B2 (ja) * 2017-04-10 2023-04-24 サイネクシス,インコーポレーテッド 併用される抗真菌剤
PL3661503T3 (pl) 2017-08-04 2023-01-09 Scynexis, Inc. Środki przeciwgrzybicze o zwiększonej aktywności przy kwasowym odczynie ph

Also Published As

Publication number Publication date
KR20210133241A (ko) 2021-11-05
JP7581219B2 (ja) 2024-11-12
US12594266B2 (en) 2026-04-07
EP3930716A1 (en) 2022-01-05
JP2022523212A (ja) 2022-04-21
WO2020176527A1 (en) 2020-09-03
IL285839A (en) 2021-10-31
BR112021016876A2 (pt) 2021-11-03
MX2021010311A (es) 2022-01-04
AU2020228036B2 (en) 2025-08-07
AU2020228036A1 (en) 2021-09-23
ES3055272T3 (en) 2026-02-10
MX2025004197A (es) 2025-09-02
US20230149376A1 (en) 2023-05-18
CA3131298A1 (en) 2020-09-03
TW202045169A (zh) 2020-12-16
EA202192344A1 (ru) 2021-11-15
CN113631165A (zh) 2021-11-09
TWI910099B (zh) 2026-01-01
EP3930716B1 (en) 2025-09-10

Similar Documents

Publication Publication Date Title
EP3893940A4 (en) COMBINATION THERAPY FOR THE TREATMENT OF MUSCULAR DYSTROPHY
MA47719A (fr) Esketamine pour le traitement de la dépression
FR24C1017I2 (fr) Utilisations d&#39;antagonistes d&#39;il-13 pour le traitement de la dermatite atopique
EP3283168A4 (en) USE OF ANTI-PACAP ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS THEREOF FOR THE TREATMENT, PREVENTION OR INHIBITION OF PHOTOPHOBY
MA47604A (fr) Anticorps anti-pd-1 pour le traitement du cancer du poumon
MA44083A (fr) Composés de biarylmonobactame pour le traitement d&#39;infections bactériennes
EP3504187A4 (en) USE OF PRIDOPIDIN FOR THE TREATMENT OF FUNCTIONAL DECAY
EP3946357A4 (en) TOPICAL FORMULATIONS FOR THE TREATMENT OF PERIPHERAL NEUROPATHIES
MA55218A (fr) Eskétamine pour le traitement de la dépression
EP3541379A4 (en) COMPOSITIONS FOR THE TREATMENT OF HYPERTONIA
MA52961A (fr) Compositions et procédés pour la réduction ou le traitement d&#39;une inflammation
EP3749342A4 (en) BACTERIOPHAGE FOR THE TREATMENT AND PREVENTION OF CARCINOMAS ASSOCIATED WITH BACTERIA
EP3863671A4 (en) MONOCLONAL ANTIBODY FOR THE TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA
EP3801478A4 (en) METHODS AND COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF CALCIPHYLAXIA
EP3430400A4 (en) DOSAGE PLANS FOR THE TREATMENT OF FUNGI INFECTIONS
EP3716966A4 (en) ALPHA-KETO ACID COMPOSITIONS FOR THE TREATMENT OF HYPOALBUMINEMIA
FR24C1053I2 (fr) Utilisation du delgocitinib pour le traitement de l&#39;eczéma des mains chronique
MA51613A (fr) Polythérapie pour le traitement ou la prévention du cancer
EP4157341A4 (en) Peptides for covid-19 prevention and treatment
EP3827831A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS
MA51615A (fr) Polytherapie pour le traitement ou la prévention du cancer
EP3953485A4 (en) HTRA1 MODULATION FOR THE TREATMENT OF AMD
EP3826633A4 (en) COMPOSITIONS FOR THE TREATMENT OF HYPERTENSION
MA52960A (fr) Compositions et procédés pour la réduction ou le traitement de la fibrose
EP4041267A4 (en) YEAST FOR ALLERGY TREATMENT